Prestige Consumer Healthcare Inc.

PBH Healthcare Drug Manufacturers Specialty & Generic

Prestige Consumer Healthcare Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.1 billion, down 4.31% from fiscal 2025.

Revenue
+22.7%
EPS
−38.4%
Free cash flow
−38.2%
Total debt
+100.9%

Quarter to September 2026, against a year earlier

43.42 0.90 −2.03%
Market cap
$2.1B
P/E
13.7×
Fwd P/E
11.7×
Dividend yield
—
F-score
5/9
Altman Z
2.48
Beneish M
−2.53
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26 From the 10-Q filed 5 Nov
ROE

+8 more TTM periods

10.31% 10.22% 9.12% 8.23%
Piotroski F-Score
5 5 4 5
ROA
5.47% 5.52% 4.30% 3.80%
ROIC
7.15% 6.82% 4.70% 9.59%
Return on Tangible Assets
44.19% 44.03% 37.38% 35.21%
Average Days of Receivables
62.99 64.34 61.89 76.35
Free Cash Flow per Share
5.58 5.09 4.96 4.51
Free Cash Flow
267.19 246.45 235.36 214.22
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026